EP1265635A1 — Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
Assigned to Glaxo Group Ltd · Expires 2002-12-18 · 23y expired
What this patent protects
Pharmaceutical combinations comprising an agent that arrests target cells in the G2 and/or M phase of the cell cycle and another therapeutic agent that targets an internalising cell surface structure such as an antigen. Use in the manufacture of a medicament and in methods of med…
USPTO Abstract
Pharmaceutical combinations comprising an agent that arrests target cells in the G2 and/or M phase of the cell cycle and another therapeutic agent that targets an internalising cell surface structure such as an antigen. Use in the manufacture of a medicament and in methods of medical treatment, particularly in the treatment of diseases of cell cycle regulation such as cancer are disclosed.
Drugs covered by this patent
- Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.